Long-term safety of risankizumab in patients with psoriatic disease: Findings from integrated analyses of 17 clinical trials in psoriasis and 4 in psoriatic arthritis

被引：0
|
作者：
Gordon, Kenneth B. [1 ]
Blauvelt, Andrew [2 ]
Bachelez, Herve [3 ]
机构：
[1] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI USA
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Hop St Louis, Serv Dermtal, Paris, France
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
34914
引用
收藏
页码：AB78 / AB78
页数：1
相关论文
共 50 条
  • [1] LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS
    Gordon, K. B.
    Blauvelt, A.
    Bachelez, H.
    Kaplan, B.
    Koetse, W.
    Drogaris, L.
    Sinvhal, R.
    Papp, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 823
  • [2] Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials
    Gordon, Kenneth
    Blauvelt, Andrew
    Coates, Laura C.
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB219 - AB219
  • [3] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
    Gordon, Kenneth
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2791 - 2793
  • [4] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
    Gordon, Kenneth B.
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura C.
    Van den Bosch, Filip E.
    Kaplan, Blair
    Koetse, Willem
    Ashley, Doug G.
    Lippe, Ralph
    Sinvhal, Ranjeeta
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2024, 14 (09) : 2523 - 2538
  • [5] Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
    Strober, Bruce
    Coates, Laura C.
    Lebwohl, Mark G.
    Deodhar, Atul
    Leibowitz, Evan
    Rowland, Katelyn
    Kollmeier, Alexa P.
    Miller, Megan
    Wang, Yanli
    Li, Shu
    Chakravarty, Soumya D.
    Chan, Daphne
    Shawi, May
    Yang, Ya-Wen
    Thaci, Diamant
    Rahman, Proton
    DRUG SAFETY, 2024, 47 (01) : 39 - 57
  • [6] Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
    Bruce Strober
    Laura C. Coates
    Mark G. Lebwohl
    Atul Deodhar
    Evan Leibowitz
    Katelyn Rowland
    Alexa P. Kollmeier
    Megan Miller
    Yanli Wang
    Shu Li
    Soumya D. Chakravarty
    Daphne Chan
    May Shawi
    Ya-Wen Yang
    Diamant Thaҫi
    Proton Rahman
    Drug Safety, 2024, 47 : 39 - 57
  • [7] TARGETED SAFETY ANALYSES OF GUSELKUMAB: LONG-TERM RESULTS FROM RANDOMIZED CLINICAL TRIALS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND MODERATE TO SEVERE PSORIASIS
    Mease, P. J.
    Foley, P.
    Reich, K.
    Chakravarty, S. D.
    Shawi, M.
    Yang, Y. W.
    Miller, M.
    Kollmeier, A.
    Xu, X. L.
    Yu, J.
    Wang, Y.
    Sheng, S.
    You, Y.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1572 - 1573
  • [8] Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
    Mease, Philip
    Foley, Peter
    Reich, Kristian
    Chakravarty, Soumya
    Shawi, May
    Yang, Ya-Wen
    Miller, Megan
    Kollmeier, Alexa
    Xu, Xie
    Yu, Jenny
    Wang, Yanli
    Sheng, Shihong
    You, Yin
    McInnes, Iain
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3760 - 3763
  • [9] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
  • [10] SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS
    Sesin, C.
    Gallo, G.
    Gellett, A.
    Kronbergs, A.
    Sprabery, A. T.
    Xu, W.
    Patel, H.
    Deodhar, A.
    Combe, B.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 789 - 789
12345